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Immune checkpoint molecules in 
natural killer cells as potential targets 
for cancer immunotherapy





Natural killer (NK) cells
• A class of lymphocytes
• Part of the innate immune response 
(do not require antibodies to function)
• In charge of “immunosurveillance”
• NK cells patrol the body for infected 
cells or foreign cells
• Kill cells that are foreign or are 
infected using cytotoxic granules
• Granulated, non-phagocytotic cells



































NK recognition of normal cells
• All nucleated body cells have a surface 
major histocompatibility complex class I 
(MHC I) on their cell surface
• When on a normal human cell, MHC I 
proteins present either self antigen or 
the antigen of a foreign agent (e.g., 
virus)
• When the self-antigen is detected by the 
NK cell, the NK is prohibited from 
attacking that cell through inhibition
• This mechanism is known as self-
tolerance
NK cells: 3 different functions
• Regulatory NK cells stimulate 
an immune response
• Cytotoxic NK cells prioritize 
killing unwanted cells
• Memory NK cells can be tied to 
the specific immune response 
through antibodies
• Takeaway: NK cells, on top of 
killing cells, can trigger a 
further immune response
Combination of inhibitory and activating 
signals on target cells
• NK cells act upon a balance of 
inhibitory and activating signals
• MHC Class I
• Self-antigen → inhibition
• Foreign antigen → activation
• Lack of MHC Class I on target cell → 
activation (may be cancer, infected 
cell, or bacteria)
• Surface Proteins on Target Cell
• Certain proteins on the target cell’s 
membrane activate or inhibit the 
cytotoxicity of NK cells
NK cell dysfunction
• Dysfunction







• Balanced inhibitory and 
activating signals → normal 
functioning
NK activation and inhibition via cell surface
• NK cells can be activated or 
inhibited via their own cell 
surface
• Molecules and receptors that 
interact with/at the cell 
surface of the NK cells are 
known as immune 
checkpoint 
molecules/receptors
• Improper regulation of these 
immune checkpoints can also 
lead to NK cell dysfunction
Potential application of NK cells: cancer
• Natural killer cells on their own kill cancer
• Providing NK cells means reduced cancer
• In patients on chemotherapy, their immune response is suppressed even 
though the cancer cell are being killed
• To reinvigorate the immune system (as well as initiative anti-tumor 
response), NK cells can be added/proliferated within the body
• Autologous transplant
• Allogeneic transplant
• However, regulating immune checkpoints can also lead to a variable NK 
response 
• Clinical trials are already in the running to investigate the effects of NK cells 
against cancer
Regulating immune checkpoint molecules
• Many immune checkpoint molecules are 
inhibitory in nature (they prevent the 
cytotoxic effects of NK cells against 
unwanted cells)
• If inhibitory immune checkpoint molecules 
are not controlled, there may be excess 
inhibition of NK cells, leading to virus or 
cancer proliferation
• Antibody immune targeting of inhibitory 
immune checkpoints → lowered inhibition 
of NK cells
Tumor microenvironment (TME)
• In the TME, the NK cells are altered, allowing cancer cells to escape 
detection
• NK cells primary do this through inhibitory receptor proteins
• KIRs contribute to recognition of self-antigen, providing inhibitory signal for 
NK activation
• PD-1 (programmed cell death protein 1) is high expressed in NK cells in the 
TMEs of certain cancers
• However, decreased activation also occurs
• NKG2D is an activating receptor on NK cells
• The concentration of NKG2D ligands is lower in the TME
Immunotherapies for cancer using NK cells
• Targeting inhibitory proteins on NK cells through antibodies could serve as 
an immunotherapeutic approach for cancer
• Monoclonal antibodies for immune checkpoint molecules involved in the 
suppression of NK cells have been shown to treat cancer
• Recent methodologies have also been developed using the mAb-mediated 
blockade of definite NK cell immune checkpoints
• Studies using immunotherapies against cancer cells have been effective
• One recent study (mentioned in the paper) found that increased activation 
of NKG2D is better than targeting  inhibitory receptors
• The use of NK cells may be of particular interest as many cancers are 
becoming chemo-resistant 
Regulatory T cell interactions
• Regulatory T cells suppress the population 
expansion of NK cells
• Downregulating T cells may be an effective 
method of increased NK populations
• However, downregulating T cells may mean a 
lowered immune response
Adenosine interactions
• Cancer cells may elicit 
adenosine generation, 
converting NK cells into 
dysfunctional cells through 
hypoxia
• Cancer tissue have large ATP 
demands
• Hypoxia convert these ATP 
molecules into ADO, 
suppressing the immune 
response 
Conclusions
• NK cells play an important role in monitoring cells within the body
• NK cells can secrete cytokines, triggering a further immune response
• NK cells can also kill unwanted cells (including cancer)
• NK cells can also provide to immunity through memory NK cells
• In the TME, NK cells are altered, leading to an imbalance of NK 
activating and inhibiting signals, contributing to NK dysfunction
• Immunotherapies targeted against immune suppression have worked, 
but activating methods also show promise
• Current methods for exploring NK-mediated immunotherapy for 
cancer should be further investigated
Discussion Questions
• Immunology is a rapidly developing field. New cellular mechanisms 
are found quite regularly. The dendritic cell, for example, was 
discovered only in 1973. How does our understanding of immunity 
change our world today?
• Cancer types are rapidly becoming chemo-resistant, meaning that 
they are resistant to chemotherapy, the traditional treatment for 
cancer. Should we switch to using NK cells to treat cancer?
• Should we rely more on combined therapeutic techniques to treat 
illnesses/diseases?
Discussion Questions
• Our bodies also can develop autoimmunity thanks to the immune 
system. Should we try to harness the immune system to kill unwanted 
cells, or should we rely on other means to fight off 
infection/illnesses?
• Cancer diagnosis and treatment can be very devastating for patients. 
How can we adopt a more holistic approach to fighting cancer?
• To function optimally, NK cells require a balance of activating and 
inhibitory signals. Does the complexity of our bodies serve as a 
hindrance towards our health?
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